Adjuvant Reirradiation With Proton Therapy in Head and Neck Squamous Cell Carcinoma

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2024 May 23

PMID 38778826

Authors

Kristin Hsieh

Alexandra Elena Hotca

Daniel R Dickstein

Eric J Lehrer

Celina Hsieh

Vishal Gupta

Kunal K Sindhu

Jerry T Liu

Samuel H Reed

Arpit Chhabra

Krzysztof Misiukiewicz

Scott Roof

Mohemmed Nazir Kahn

Diana Kirke

Mark Urken

Marshall Posner

Eric Genden

Richard L Bakst

Affiliations

Soon will be listed here.

Abstract

Purpose: For patients with head and neck squamous cell carcinoma (HNSCC), locoregional failure and second primary tumors are common indications for adjuvant reirradiation (re-RT). Given an absence of clear consensus on the role of adjuvant re-RT, we sought to assess histopathologic risk factors of patients with HNSCC and their resulting outcomes after adjuvant re-RT with proton therapy.

Methods And Materials: We conducted a retrospective analysis of patients with HNSCC who underwent salvage surgery at our institution followed by adjuvant re-RT with proton therapy over 1.5 years. All included patients received prior radiation therapy. The Kaplan-Meier method was used to evaluate locoregional recurrence-free survival and overall survival.

Results: The cohort included 22 patients, with disease subsites, including oropharynx, oral cavity, hypopharynx, larynx, and nasopharynx. Depending on adverse pathologic features, adjuvant re-RT to 66 Gy (32% of cohort) or 60 Gy (68%), with (59%) or without (41%) concurrent systemic therapy was administered. The majority (86%) completed re-RT with no reported treatment delay; 3 patients experienced grade ≥3 acute Common Terminology Criteria for Adverse Events toxicity and no patient required enteral feeding tube placement during re-RT. Median follow-up was 21.0 months (IQR, 11.7-25.2 months). Five patients had biopsy-proven disease recurrences a median of 5.9 months (IQR, 3.8-9.7 months) after re-RT. Locoregional recurrence-free survival was 95.2%, 70.2%, 64.8% at 6, 12, and 24 months, respectively. OS was 100%, 79.2%, and 79.2% at 6, 12, and 24 months, respectively. Four patients had osteoradionecrosis on imaging a median of 13.2 months (IQR, 8.7-17.4 months) after re-RT, with 2 requiring surgical intervention.

Conclusions: Adjuvant re-RT for patients with HNSCC was well-tolerated and offered reasonable local control in this high-risk cohort but appears to be associated with a risk of osteoradionecrosis. Additional study and longer follow-up could help define optimal patient management in this patient population.

References

Lupato V, Giacomarra V, Alfieri S, Fanetti G, Polesel J . Prognostic factors in salvage surgery for recurrent head and neck cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 169:103550. DOI: 10.1016/j.critrevonc.2021.103550. View

Langer C, Harris J, Horwitz E, Nicolaou N, Kies M, Curran W . Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25(30):4800-5. DOI: 10.1200/JCO.2006.07.9194. View

Romesser P, Cahlon O, Scher E, Hug E, Sine K, DeSelm C . Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes. Int J Radiat Oncol Biol Phys. 2016; 95(1):386-395. PMC: 4997784. DOI: 10.1016/j.ijrobp.2016.02.036. View

Cramer J, Burtness B, Le Q, Ferris R . The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019; 16(11):669-683. DOI: 10.1038/s41571-019-0227-z. View

Lee A, Woods R, Mahfouz A, Kitpanit S, Cartano O, Mohamed N . Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. JAMA Netw Open. 2023; 6(1):e2250607. PMC: 9871797. DOI: 10.1001/jamanetworkopen.2022.50607. View

Haque S, Karivedu V, Riaz M, Choi D, Roof L, Hassan S . High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma. Oral Oncol. 2019; 88:9-15. PMC: 6327963. DOI: 10.1016/j.oraloncology.2018.11.010. View

Phan J, Sio T, Nguyen T, Takiar V, Gunn G, Garden A . Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016; 96(1):30-41. DOI: 10.1016/j.ijrobp.2016.03.053. View

Ben Arie G, Shafat T, Belochitski O, El-Saied S, Joshua B . Treatment Modality and Second Primary Tumors of the Head and Neck. ORL J Otorhinolaryngol Relat Spec. 2021; 83(6):420-427. PMC: 8686706. DOI: 10.1159/000513617. View

Margalit D, Sacco A, Cooper J, Ridge J, Bakst R, Beadle B . Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria. Head Neck. 2020; 43(1):367-391. PMC: 7756212. DOI: 10.1002/hed.26490. View

10.

Sulman E, Schwartz D, Le T, Ang K, Morrison W, Rosenthal D . IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2008; 73(2):399-409. DOI: 10.1016/j.ijrobp.2008.04.021. View

11.

Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G . Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers (Basel). 2021; 13(10). PMC: 8155962. DOI: 10.3390/cancers13102371. View

12.

Lupato V, Polesel J, La Torre F, Fanetti G, Fratta E, Gobitti C . A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas. Sci Rep. 2021; 11(1):502. PMC: 7804332. DOI: 10.1038/s41598-020-79759-0. View

13.

Milano M, Vokes E, Salama J, Stenson K, Kao J, Witt M . Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005; 61(4):1096-106. DOI: 10.1016/j.ijrobp.2004.08.029. View

14.

Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A . An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy. Cancers (Basel). 2021; 13(19). PMC: 8508236. DOI: 10.3390/cancers13194912. View

15.

Verma V, Rwigema J, Malyapa R, Regine W, Simone 2nd C . Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol. 2017; 125(1):21-30. DOI: 10.1016/j.radonc.2017.08.005. View

16.

Eekers D, Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F . Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016; 121(3):387-394. DOI: 10.1016/j.radonc.2016.08.020. View

17.

Chow L . Head and Neck Cancer. N Engl J Med. 2020; 382(1):60-72. DOI: 10.1056/NEJMra1715715. View

18.

Elbers J, Al-Mamgani A, van den Brekel M, Jozwiak K, de Boer J, Lohuis P . Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Otolaryngol Head Neck Surg. 2018; 160(6):1023-1033. DOI: 10.1177/0194599818818443. View

19.

Nguyen-Tan P, Zhang Q, Ang K, Weber R, Rosenthal D, Soulieres D . Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014; 32(34):3858-66. PMC: 4239304. DOI: 10.1200/JCO.2014.55.3925. View

20.

Adjei Boakye E, Buchanan P, Hinyard L, Osazuwa-Peters N, Schootman M, Piccirillo J . Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2018; 144(8):727-737. PMC: 6142994. DOI: 10.1001/jamaoto.2018.0993. View